Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Ivacaftor/lumacaftor/ivacaftor/tezacaftor

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Breuer O, et al. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?. Chest 161: 773-780, No. 3, Mar 2022. Available from: URL: http://www.chestjournal.org/ Breuer O, et al. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?. Chest 161: 773-780, No. 3, Mar 2022. Available from: URL: http://​www.​chestjournal.​org/​
Metadaten
Titel
Ivacaftor/lumacaftor/ivacaftor/tezacaftor
Lack of efficacy: case report
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30915-7

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Oxaliplatin

Case report

Tozinameran